Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity

Synapse

Volumn 65, Issue 2, 2011, Pages 154-159

  Szobot, Claudia M ^a,b,c   Roman, Tatiana ^b   Hutz, Mara H ^b   Genro, Júlia P ^b   Shih, Ming Chi ^d   Hoexter, Marcelo Q ^d   Júnior, Neivo ^e   Pechansky, Flávio ^b   Bressan, Rodrigo A ^d   Rohde, Luis A P ^a,f  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e Universidade Federal de São Paulo ^*  (Brazil)

^f Instituto Nacional de Psiquiatria do Desenvolvimento (INPD)   (Brazil)

Author keywords

Attention deficit hyperactivity disorder; DAT1; DRD4; Methylphenidate; SPECT; Substance use disorders

Indexed keywords

[TECHNETIUM 99M]TRODAT 1; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER 1; METHYLPHENIDATE; RADIOISOTOPE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMORBIDITY; GENE; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; MOLECULAR GENETICS; MOLECULAR IMAGING; PRIORITY JOURNAL; PUTAMEN; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; BRAIN MAPPING; COMORBIDITY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; MALE; METHYLPHENIDATE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D4; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 78649987719     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20829     Document Type: Article

References (41)

1. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T. 2009. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 29: 239-247.
2. Amorim P. 2000. Mini International Neuropsychiatric Interview (MINI): Validação de entrevista breve para diagnóstico de transtornos mentais. Revista Bras Psiquiatr 22: 106-115.
3. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S, Zamora-Paja E, Farahi J, Saxena S, London ED, McCracken JT. 2006. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
4. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA., Krabbe PF. 2005. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100: 1868-1874.
5. Cheon KA, Ryu YH, Kim JW, Cho DY. 2005. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15: 95-101.
6. 99m]TRODAT-1. Nucl Med Biol 26: 461-466.
7. Daws LC, Callaghan PD, Moron JA, Kahlig KM, Shippenberg TS, Javitch JA, Galli A. 2002. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290: 1545-1550.
8. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. 1999. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet18-25; 354: 2132-2133.
9. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27: 1518-1524.
10. Ercan ES, Coskunol H, Varan A, Toksoz K. 2003. Childhood attention deficit/hyperactivity disorder and alcohol dependence: A 1-year follow-up. Alcohol Alcohol 38: 352-356.
11. Faraone SV, Khan SA. 2006. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry 67(Suppl 8): 13-20.
12. Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O'Gara C, Bubb VJ, Greenwood T, Kelsoe J, Asherson P, Murray RM, Castelo A, Quinn JP, Vallada H, Breen G. 2006. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 21; 103: 4552-4557.
13. Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. 2004. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: A pharmacogenetic study. J Child Adolesc Psychopharmacol 14: 564-574.
14. Krain AL, Castellanos FX. 2006. Brain development and ADHD. Clin Psychol Rev 26: 433-444.
15. Lahiri DK, Nurnberger JI. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nuclei Acids Res 19: 5444.
16. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, Muller HW. 2006. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 27: 267-270.
17. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. 2006. Treatment of methadone-maintained patients with adult ADHD: Double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81: 137-148.
18. Levin FR, Evans SM, Brooks DJ, Garawi F. 2007. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87: 20-29.
19. Liu F, Muniz R, Minami H, Silva RR. 2005. Review and comparison of the long acting methylphenidate preparations. Psychiatr Q 76: 259-269.
20. Mattos P, Serra Pinheiro MA, Rohde LA, Pinto D. 2006. A Brazilian version of the MTA-SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and oppositional-defiant disorder. Rev Psiquiatr Rio Gd Sul 28:290-297.
21. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK. 2008. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 15; 63: 981-989.
22. Mercadante MT, Asbarch F, Rosário MC, Ayres AM, Ferrari MC, Assumpção FB, et al. 1995. K-SADS, 1° edição. São Paulo, SP: Protoc - Hospital das Clínicas da FMUSP.
23. Oak JN, Oldenhof J, Van Tol HH. 2002. The dopamine D(4) receptor: One decade of research. Eur J Pharmacol 405: 303-327.
24. Ollendick TH, Jarrett MA, Grills-Taquechel AE, Hovey LD, Wolff JC. 2008. Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/conduct disorders. Clin Psychol Rev 8: 1447-1471.
25. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M. 2006. Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 642-657.
26. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WEJ, Fallon JH, Kennedy JL. 2003. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 8: 109-113.
27. Renthal W, Nestler EJ. 2008. Epigenetic mechanisms in drug addiction. Trends Mol Med 14: 341-350.
28. Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. 2005. Attention-deficit/hyperactivity disorder in a diverse culture: Do research and clinical findings support the notion of a cultural construct for the disorder? Biol Psychiatry 1; 57: 1436-1441.
29. Rohde LA, Szobot CM, Roman T, Cunha R, Hutz M, Biederman J. 2003. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in ADHD: A pilot study. Synapse 48: 87-89.
30. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH. 2001. Attention-deficit/hyperactivity disorder: A study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am J Med Genet (Neuropsychiatr Genet) 105: 471-478.
31. Roman T, Rohde LA, Hutz MH. 2004. Polymorphisms of the dopamine transporter gene: Influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics 4: 83-92.
32. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154: 1209-1213.
33. Seeger G, Schloss P, Schmidt MH. 2001. Marker gene polymorphisms in hyperkinetic disorder-predictors of clinical response to treatment with methylphenidate? Neurosci Lett 313: 45-48.
34. Shao C, Li Y, Jiang K, Zhang D, Xu Y, Lin L, Wang Q, Zhao M, Jin L. 2006. Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology 186: 185-190.
35. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M. 2001. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40: 168-179.
36. Szobot CM, Bukstein O. 2008. Attention-Deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatric Clinics North Am 17: 309-323.
37. (99m)]TRODAT-1 study. NeuroImage 40: 1195-1201.
38. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey S, Ashby C, Liebermann J, Hitzemann R, et al. 1995. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52: 456-463.
39. Volkow ND, Fowler JS, Wang GJ. 2004. The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology 47(Suppl 1): 3-13.
40. Walker R. 2009. Retention in treatment-indicator or illusion: An essay. Subst Use Misuse 44: 18-27.
41. White AM, Jordan JD, Schroeder KM, Acheson SK, Georgi BD, Sauls G, Ellington RR, Swartzwelder HS. 2004. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. Subst Abus 25: 53-59.